What is the recommended management approach for medullary thyroid cancer, including surgery, genetic testing, postoperative monitoring, and systemic therapy options?

Medullary Thyroid Cancer Management

Surgical Management

Total thyroidectomy with bilateral central neck dissection (level VI) is the primary curative treatment for all medullary thyroid cancer (MTC) tumors ≥1 cm or bilateral disease, because MTC cells do not concentrate radioiodine and do not respond to conventional chemotherapy. 1

Surgical Extent by Tumor Characteristics

• For tumors <1 cm with unilateral disease, total thyroidectomy is recommended and neck dissection can be considered based on preoperative calcitonin levels and ultrasound findings 1
• Bilateral central neck dissection (level VI) is indicated for all patients with tumors ≥1 cm 1
• More extensive lateral neck dissection (levels II–V) should be performed for primary tumors ≥1 cm or when central compartment lymph node metastases are present 1
• For MEN 2B patients, consider lateral neck dissection for tumors >0.5 cm 1

Critical Pre-operative Screening

• All patients must undergo RET proto-oncogene mutation testing before surgery to distinguish sporadic from hereditary disease, even in apparently sporadic cases, because approximately 6% harbor germline mutations 2
• Pheochromocytoma screening with plasma metanephrines and normetanephrines is mandatory before any thyroid surgery in hereditary cases; failure to diagnose and treat pheochromocytoma first can cause fatal intraoperative hypertensive crisis 1
• For MEN 2A patients, measure serum calcium and intact parathyroid hormone to screen for hyperparathyroidism 1
• Obtain baseline serum calcitonin and carcinoembryonic antigen (CEA) levels 1, 2
• Perform neck ultrasound to evaluate thyroid and cervical lymph nodes 1, 2
• Consider contrast-enhanced chest CT or MRI if lymph node involvement is present or calcitonin >400 pg/mL 1, 2

Prophylactic Thyroidectomy for RET Mutation Carriers

MEN 2B (Highest Risk: Codon 918,883, or Compound Heterozygous Mutations)

• Total thyroidectomy must be performed within the first year of life, ideally before age 1, because these mutations produce the most aggressive MTC with earliest onset 1, 2
• Consider bilateral central neck dissection (level VI) at the time of prophylactic surgery 1
• Consider more extensive node dissection (levels II–V) if tumor(s) >0.5 cm in diameter are identified 1

MEN 2A (Codons 609,611,618,620,630,634)

• Total thyroidectomy should be performed by age 5 years, or immediately when the mutation is identified if diagnosed at an older age 1, 2
• Codon 634 mutations are the most common RET mutation in MEN 2A 1
• Therapeutic ipsilateral or bilateral central neck dissection (level VI) is recommended if calcitonin or CEA is elevated or ultrasound shows thyroid or nodal abnormality 1

Lower-Risk RET Mutations (Codons 768,790,791,804,891)

• Surgery may be delayed beyond age 5 if annual basal calcitonin is normal, annual ultrasound is unremarkable, there is no family history of aggressive MTC, and the family agrees to this approach 1, 2
• These mutations are associated with lower lethality and later onset of MTC development 1, 2
• When surgery is performed, total thyroidectomy with central node dissection is recommended 1

Post-operative Management

Levothyroxine Replacement

• Maintain TSH in the normal laboratory reference range; do NOT suppress TSH, because MTC cells lack TSH receptors and suppression provides no oncologic benefit 1, 3
• Adjust levothyroxine dose to keep TSH normal, fundamentally different from papillary or follicular thyroid cancer management 1, 3

Tumor Marker Surveillance

• Measure serum calcitonin and CEA every 6 months for the first 2–3 years, then annually 4
• Calculate calcitonin and CEA doubling times from sequential measurements, as these are paramount for assessing disease progression 4
• Calcitonin levels >150 pg/mL are associated with distant metastases and mandate thorough imaging evaluation 4
• Rapidly increasing CEA levels, particularly with stable calcitonin, predict worse prognosis 4

Imaging for Persistent or Recurrent Disease

• Neck ultrasound is the first-line imaging modality for detecting local recurrence and cervical lymph node metastases 5
• Never use radioiodine imaging to screen for MTC recurrence, because MTC cells do not concentrate radioactive iodine 1, 3
• For calcitonin >400 pg/mL or documented lymph node involvement, obtain contrast-enhanced chest CT and three-phase contrast-enhanced liver CT or MRI 1, 2
• Consider bone scintigraphy and MRI of spine/pelvis for complete metastatic survey 4

Lifelong Surveillance for Hereditary Cases

• Annual screening for pheochromocytoma (MEN 2A and 2B) and hyperparathyroidism (MEN 2A) must continue for life after thyroidectomy 1, 2, 3
• For lower-risk mutations (codons 768,790,804,891), less frequent surveillance intervals may be appropriate 1, 2, 3
• Monitor serum calcium closely in the immediate postoperative period and long-term to detect hypoparathyroidism, the most common major complication after total thyroidectomy 3

Systemic Therapy for Advanced Disease

Indications for Systemic Therapy

• Systemic therapy is reserved for patients with progressive, symptomatic, or high-burden metastatic disease that is not amenable to surgical resection 6
• Conventional cytotoxic chemotherapy (dacarbazine, 5-fluorouracil, doxorubicin) has very limited efficacy, achieving only 10–20% partial response rates of short duration 7

Targeted Therapy Options

• Selective RET inhibitors (selpercatinib, pralsetinib) are the preferred first-line agents for RET-mutated MTC, offering high efficacy with fewer side effects compared to multikinase inhibitors 6
• Multikinase inhibitors (vandetanib, cabozantinib) extend progression-free survival by targeting tumor growth and angiogenesis but cause more off-target effects 6
• Vandetanib and cabozantinib remain options for advanced MTC, particularly in RET-negative cases 6

Genetic Counseling and Family Screening

• All first-degree relatives of patients with hereditary MTC, MEN 2A, or MEN 2B must receive RET genetic testing to identify carriers before symptoms develop 2
• RET mutations are identified in ≥95% of MEN 2A families and approximately 88% of familial MTC families 2
• Approximately 25% of all MTC cases are hereditary (MEN 2A, MEN 2B, or familial MTC) 2

Critical Pitfalls to Avoid

• Never proceed to thyroidectomy without first confirming the absence of pheochromocytoma in hereditary or RET-positive cases; this can cause fatal hypertensive crisis intraoperatively 1, 2
• Do not assume a case of sporadic MTC is truly sporadic without RET testing, as approximately 6% harbor germline mutations 2
• Refer very young children (especially those with MEN 2B or high-risk MEN 2A mutations) to surgeons and multidisciplinary teams experienced in pediatric thyroid surgery 1, 2
• Do not rely on routine calcitonin screening in the general population with thyroid nodules; only approximately 3% have elevated calcitonin and only 40% of those will have MTC at thyroidectomy 2
• Avoid excessive levothyroxine dosing aimed at TSH suppression, as it provides no oncologic benefit and may cause adverse effects 3